Antioxidative compositions

ABSTRACT

This invention relates to a composition that contains quercetin, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin C, caffeine, epigallocatechin gallate, epicatechin, epicatechin gallate, epigallocatechin, and polypheron E.

CROSS REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of U.S. Utility applicationSer. No. 10/302,544, filed Nov. 22, 2002, now U.S. Pat. No. 6,821,536the contents of which are incorporated herein by reference.

BACKGROUND

It is known that certain natural antioxidants, such as plant flavonoids,inhibit both acute and chronic phases of free-radical induced diseases.Further, some natural antioxidants exhibit synergy in their reactionswith biologically relevant oxygen species, e.g., hydroxyl radicals,superoxides, oxysulfurs, sulfur dioxide, and nitrogen dioxide. Forexample, studies have shown synergistic antioxidative activities ofvitamin C and phenolic antioxidants.

SUMMARY

This invention is based on the unexpected discovery that quercetin, anantioxidant, and a number of other natural products exhibit synergistichealth benefits.

The invention features a composition that contains the followingingredients: vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitaminB12, vitamin C, caffeine, quercetin, epigallocatechin gallate,epicatechin, epicatechin gallate, epigallocatechin, and polypheron E.This composition may also contain other ingredients, such as vitamin E,CoQ-10, soy isoflavones, taurine, sugar beet pectin fiber, and a ginkobiloba extract. Further, the composition can be sweetened, if necessary,by adding a sweetener, e.g., sorbitol, maltitol, cane sugar, highfructose corn syrup, and the like. The composition can also containamino acids, minerals, a flavor enhancer, or a coloring agent. It isknown that the leaves of green tea contain epigallocatechin gallate,epicatechin, epicatechin gallate, epigallocatechin, and polypheron E.Thus, these five ingredients can be conveniently provided as a green teaextract.

The composition of the invention can be in dry form (e.g., powder ortablet) or in aqueous form (e.g., beverage or syrup). It can be adietary supplement or a pharmaceutical formulation. It can also be adrink or a food product. Examples include tea (e.g., a tea drink and thecontents of a tea bag), soft drinks, juice (e.g., a fruit extract and ajuice drink), milk, coffee, cookies, cereals, chocolates, and snackbars. The composition, in any of the forms described above, can be usedto treat arthritis, tumor, sexual dysfunction, chronic constipation,inflammatory bowel disease; improving concentration or mood; andlowering cholesterol levels or blood pressure. Also within the scope ofthis invention is a composition of the invention as an active agent, aswell as use of the composition for the manufacture of a medicament, fortreating the above-mentioned diseases.

The details of one or more embodiments of the invention are set forth inthe accompanying description below. Other features, objects, andadvantages of the invention will be apparent from the description andfrom the claims.

DETAILED DESCRIPTION

A composition of this invention contains vitamin B1, vitamin B2, vitaminB3, vitamin B6, vitamin B12, vitamin C, caffeine, quercetin,epigallocatechin gallate, epicatechin, epicatechin gallate,epigallocatechin, and polypheron E. A green tea extract can beconveniently used to provide epigallocatechin gallate, epicatechin,epicatechin gallate, epigallocatechin, and polypheron E.

Exemplary quantities of the ingredients of this composition are: 0.1-50mg (e.g., 20-50 mg) of vitamin B1, 0.1-150 mg (e.g., 10-150 mg) ofvitamin B2, 0.1-2000 mg (e.g., 10-2000 mg) of vitamin B3, 0.1-200 mg(e.g., 10-200 mg) of vitamin B6, 5-150 μg (e.g., 10-150 μg) of vitaminB12, 50-2000 mg (e.g., 50-1000 mg) of vitamin C, 50-1500 mg (e.g.,50-1000 mg) of caffeine, 20-2000 mg (e.g., 50-2000 mg) of quercetin,10-500 mg (e.g., 20-500 mg) of epigallocatechin gallate, 10-500 mg(e.g., 20-400 mg) of epicatechin, 10-500 mg (e.g., 20-400 mg) ofepicatechin gallate, 10-500 mg (e.g., 20-400 mg) of epigallocatechin,and 10-500 mg (e.g., 20-400 mg) of polypheron E, either dissolved ordispersed in a 1 L aqueous solution (which can contain a co-solvent,such as an alcohol) or in the form of powder, tablet, paste, and thelike. In the latter case, the ingredients are in quantities of the samerelative ratio to those listed above. The term “quercetin” refers toboth quercetin aglycon and quercetin derivatives, e.g.,quercetin-3-O-glucoside, quercetin-5-O-glucoside,quercetin-7-O-glucoside, quercetin-9-O-glucoside,quercetin-3-O-rutinoside,quercetin-3-O-[α-rhamnosyl-(1→2)-α-rhamnosyl-(1→6)]-β-glucoside,quercetin-3-O-galactoside, quercetin-7-O-galactoside,quercetin-3-O-rhamnoside, and quercetin-7-O-galactoside. Afterdigestion, quercetin derivatives are converted to quercetin aglycon, anactive form absorbed in the body. The quantity of quercetin mentionedabove refers to that of quercetin aglycon or the quercetin moiety of aquercetin derivative. As an example, a composition for daily use can bea 1 L aqueous solution containing 1000 mg of quercetin, 30 mg of vitaminB1, 85 mg of vitamin B2, 1 g of vitamin B3, 100 mg of vitamin B6, 120 μgof vitamin B12, 1200 mg of vitamin C, 1000 IU of vitamin E, 1000 mg ofcaffeine, and a green tea extract containing 120 mg of epigallocatechingallate, 140 mg of epicatechin, 360 mg of epicatechin gallate, 360 mg ofepigallocatechin, and 120 mg of polypheron E.

This composition may further contain one or more other activeingredients, such as vitamin E, CoQ-10, soy isoflavones, taurine, sugarbeet pectin fiber, and a ginko biloba extract. Exemplary quantities ofthese ingredients are: 3-1000 IU (e.g., 10-1000 IU) of vitamin E, 10-400mg (e.g., 20-400 mg) of CoQ-10, 20-600 mg (e.g., 30-500 mg) of soyisoflavones, 10-1000 mg (e.g., 50-1000 mg) of taurine, 1-15 g (e.g.,5-15 g) of sugar beet pectin fiber, and 50-500 mg (e.g., 50-300 mg) of aginko biloba extract (dry weight), either dissloved in a 1 L aqueoussolution or in another suitable form (e.g., powder, tablet, or paste).In the latter case, the ingredients are in quantities of the samerelative ratio to those listed above. Further, the composition can besweetened, if necessary, by adding a sweetener such as sorbitol,maltitol, hydrogenated glucose syrup and hydrogenated starchhydrolyzate, high fructose corn syrup, cane sugar, beet sugar, pectin,and sucralose.

An example of the above-described composition is a powder. It can beused conveniently to prepare beverages, e.g., tea or juice. The powdercan also be used to prepare paste, jelly, capsules, or tablets. Lactoseand corn starch are commonly used as diluents for capsules and ascarriers for tablets. Lubricating agents, such as magnesium stearate,are typically added to form tablets.

The composition of this invention can also be a dietary supplement or apharmaceutical formulation. As a dietary supplement, additionalnutrients, such as minerals or amino acids may be included. Thecomposition can also be a drink or a food product, e.g., tea, softdrinks, juice, milk, coffee, cookies, cereals, chocolates, and snackbars.

The composition, in any of the forms described above, can be used fortreating diseases or disorders, such as arthritis, tumor, sexualdysfunction, chronic constipation, inflammatory bowel disease; improvingconcentration or mood; and lowering cholesterol levels or bloodpressure. The term “tumor” refers to benign tumor, as well as malignanttumor (e.g., leukemia, colon cancer, kidney cancer, liver cancer, breastcancer, or lung cancer). The terms “treating”, “improving”, and“lowering” refer to the administration of an effective amount of acomposition of the invention to a subject, who has one or more of thejust-mentioned diseases or disorders, or a symptom or a predispositionof one of more of them, with the purpose to cure, alleviate, relieve,remedy, or ameliorate one or more of the diseases or disorders, or thesymptoms or the predispositions of one or more of them. The term“administration” covers oral or parenteral delivery to a subject acomposition of the invention in any suitable form, e.g., food product,beverage, tablet, capsule, suspension, and solution. The term“parenteral” refers to subcutaneous, intracutaneous, intravenous,intramuscular, intraarticular, intraarterial, intrasynovial,intrasternal, intrathecal, intralesional, and intracranial injection, aswell as various infusion techniques. The term “effective amount” refersto a dose of the composition that is sufficient to provide a therapeuticbenefit, e.g., lowering cholesterol levels or blood pressure. Both invivo and in vitro studies can be conducted to determine optimaladministration routes and doses.

The specific examples below are to be construed as merely illustrative,and not limitative of the remainder of the disclosure in any waywhatsoever. Without further elaboration, it is believed that one skilledin the art can, based on the description herein, utilize the presentinvention to its fullest extent. All publications cited herein arehereby incorporated by reference in their entirety.

Formulation 1 was prepared as follows. To 30 mL purified water wereadded: vitamin B1 (8 mg), vitamin B2 (21.1 mg), vitamin B3 (248 mg),vitamin B6 (24.8 mg), vitamin B12 (20.4 mg), vitamin C (74.4 mg),vitamin E (37.2 IU), caffeine (99.2 mg), quercetin aglycon (248 mg), anda green tea extract containing epigallocatechin gallate (80 mg),epicatechin (80 mg), epicatechin gallate (80 mg), epigallocatechin (80mg), and polypheron E (80 mg) at room temperature. All ingredients canbe obtained from Spectrum Laboratory Products, Inc., Gardena, Calif.;Sigma, St. Louis, Mo.; and Aldrich, Milwaukee, Wis. The above mixturewas vigorously stirred by using a food mixer and then diluted up to 200mL with purified water.

In one experiment, male Spregue-Dawley rats (150-180 gram; Charles RiverLab, Boston, Mass.) were kept in filter-topped cages with free access tofood and water, and housed in a positive pressure room with controlledtemperature and photoperiod during studies. As an animal model forinflammatory bowel disease (e.g., Crohn's disease), colitis (colongrowth caused by inflammation) was induced by intracolonic instillationof 25 mg of a hapten reagent, 2,4-dinitrobenzenesulfonic acid (TCI,Japan), in 0.5 ml of 30% vol/vol ethanol. Each rat was firstanaesthetized with metafane and then DNBS/ethanol was injected into thecolon, 8 cm proximal to the anus, with a PE 50 cannula. 2 ml of air wasthen gently injected through the cannula to ensure that the solutionremained in the colon. The rat was then kept in a vertical position for30 second and returned to its cage. By using the same procedures, ratsin the blank-control group received 0.5 ml of 30% ethanol. See Hogaboam,et al., Eur. J. Pharmacol. (1996) 309:261-269. Fomulation 1 and aquercetin aglycon solution, in which methylcellulose (MC) was added toreach a final concentration of 1%, were respectively fed to the ratsorally once a day for 7 days. Each daily dose contained 3.125 mg to 25mg of quercetin aglycon for each kilogram of body weight. The weight ofeach rat was monitored every 24 hours. At day 7, rats were killed andtheir colon were removed and weighed. Before removal of each colon, thepresence or absence of adhesions between the colon and other organs wererecorded upon opening the abdominal cavity. The colon-to-body weightratio was then calculated for each animal. The net increase in ratio ofthe vehicle-control group relative to the blank-control group was usedas a base value for comparison with the treated groups. Both formulation1 and quercetin aglycon inhibited colon growth at the dosage of 25 mg/kgand failed to do so at the dosage of 3.125 mg/kg. However, at 6.25 mg/kgand 12.5 mg/kg, formulation 1 was much more efficacious than quercetinaglycon in inhibiting colon growth.

In another experiment, a 10 mg/mL bacterial suspension was prepared bysuspending ground, heat-killed Mycobacterium tuberculosis H37Ra inincomplete Freund's adjuvant. Adjuvant arthritis (AA) was then inducedin female Lewis rats by an intracutaneous injection into the base of thetail with 0.1 ml of the above suspension. The rats were then orallygiven formulation 1 or a quercetin aglycon solution (1% MC) once a dayfor 12 days at a daily dose of 25 mg/kg quercetin aglycon, starting theday following the induction. The development of polyarthritis wasmonitored daily by macroscopic inspection and assignment of an arthritisindex to each animal, during the critical period (from day 10 to day 25after immunization). The intensity of polyarthritis was scored accordingto the following scheme: (a) Grades for each paw range from 0 to 3 basedon erythema, swelling, and deformity of the joints, i.e., 0 for noerythema or swelling; 0.5 if swelling is detectable in at least onejoint; 1 for mild swelling and erythema; 2 for swelling and erythema ofboth tarsus and carpus; and 3 for ankylosis and bone deformity. (b)Grades for other body parts: 0.5 for redness and another 0.5 for knotsin each ear; 1 for connective tissue swelling in the nose; and 1 forknots or kinks in the tail. See Schorlemmer et al., Drugs Exptl. Clin.Res. (1991) 17:471-483. Compared with the rats treated with quercetinaglycon, those treated with formulation 1 showed much more significantamelioration in arthritis symptoms at day 18.

In still another experiment, female BD2F1 (C57BL/6×DBA/2 F1) rats werefirst obtained from Charles River Lab. The rats were supplied with foodand water adlibitum. As an animal model for cancer, 50,000 cells of p388leukemia were inoculated intraperitoneally into 7-week old female BD2F1rats at day 0. Formulation 1 or a quercetin aglycon solution (1% MC) wasadministered orally once a day for 14 days at a daily dose of 12.5 mg/kgquercetin aglycon. All rats in the control group, but not those in thetreated groups, died around day 21 as a result of ascites. Theanti-cancer activity was determined by comparing the mean survival timeof the treated group with that of the control group. See Yoshimatsu etal., Cancer Res. (1997) 57:3208-3213. Rats treated with formulation 1showed a substantial longer mean survival time than those treated withquercetin aglycon.

Phosphodiesterase-5 (PDE-5) is an enzyme involved in sexual function. Ina further experiment, PDE-5 activity was determined according to awell-known method with some modifications. See Thompson et al., MethodsEnzymol. (1974) 38:205-212. Activity of purified PDE-5 was measured in areaction mixture of pH 7.5 containing 8 μM cGMP (64 μCi/ml of[³H]-cGMP), 40 mM MOPS, 0.5 mM EGTA, 15 mM magnesium acetate, and 0.15mg/ml BSA in the presence of formulation 1, a quercetin aglyconsolution, and a 3-isobutyl-1-methylxanthine (IBMX, a general PDE-5inhibitor) solution (1% MC) at various concentrations ranging from 1 μMto 100 μM. The reaction was performed at 37° C. for 60 min, andterminated by heating at 70° C. for 2 min. The labeled enzymaticreaction product [³H]-GMP was then degraded into [³H]-guanosine andphosphate in the presence of 0.1 units of nucleotidase. Finally,undegraded [³H]-cGMP was absorbed onto anion exchange resin.[³H]-Guanosine in the supernatant was counted for radioactivity in aliquid scintillation counter. It was found that formulation 1 inhibitedPDE-5 activities in a dose-dependent manner with an IC50 value muchlower than those of quercetin aglycon and IBMX.

Human studies were also conducted to evaluate two other compositions ofthis invention, i.e., formulations 2 and 3. Formulation 2 was preparedas follows. To 200 mL purified water were added: vitamin B1 (30 mg),vitamin B2 (85 mg), vitamin B3 (1 g), vitamin B6 (100 mg), vitamin B12(120 μg), vitamin C (1200 mg), vitamin E (1000 IU), caffeine (1000 mg),quercetin aglycon (1000 mg), and a green tea extract containingepigallocatechin gallate (120 mg), epicatechin (140 mg), epicatechingallate (360 mg), epigallocatechin (360 mg), and polypheron E (120 mg)at room temperature. The mixture was vigorously stirred by using a foodmixer and then diluted up to 1 L with purified water. Formulation 3 wasprepared as follows. To 200 mL purified water were added: vitamin B1(3.75 mg), vitamin B2 (4.25 mg), vitamin B3 (50 mg), vitamin B6 (5 mg),vitamin B12 (15 μg), vitamin C (150 mg), vitamin E (7.5 IU) and caffeine(200 mg), quercetin aglycon (50 mg), and a green tea extract containingepigallocatechin gallate (30 mg), epicatechin (35 mg), epicatechingallate (90 mg), epigallocatechin (90 mg), and polypheron E (30 mg) atroom temperature. The above mixture was vigorously stirred by using afood mixer. The mixture was then diluted up to 1 L with purified waterand orange juice so that the final solution contained 10% by weightorange juice.

In one study, four male subjects and four female subjects suffering fromhigh cholesterol levels and high blood pressure were treated withformulation 2. Each of the subjects drank 1 bottle of formulation 2 (20fl. oz., or 591 mL) daily for 10 days. Then, half of the group (one malesubject and 3 female subjects) continued to drink 1 bottle of the sameformulation daily for another 20 days. The other half of the groupstopped this regimen for 5 days and then started drinking 2 bottles ofthe same formulation daily for 20 days. It was found that all subjectshad improved concentration and mood. Their cholesterol levels and bloodpressure were down to normal range. No significant weight losses wereobserved among the subjects. Two subjects in each of the two half groupsfelt thirsty during this study.

In another study, two male subjects and two female subjects drank 2bottles of formulation 2 (20 fl. oz. each bottle) daily for one month.It was found that all subjects had improved mood and sex drive. Allsubjects experienced weight losses ranging from 10-25 pounds (2-6% bodyweight). After termination of this regimen, most subjects had moodswings.

In still another study, one male subject and three female subjectssuffering from serious constipation were treated with formulation 3.Each drank 1-3 bottles of formulation 3 (20 fl. oz. each bottle) dailyfor 1 week. Constipation was relieved for all subjects.

In yet another study, a male subject, who suffered from Crohn's diseaseand had symptoms of stomach ache and diarrhea, was also treated withformulation 3. The subject drank 2 bottles of formulation 3 (20 fl. oz.each bottle) daily for 1 week. Both symptoms were dramatically reducedand the effects were sustained for at least one week after terminationof the regimen.

OTHER EMBODIMENTS

All of the features disclosed in this specification may be combined inany combination. Each feature disclosed in this specification may bereplaced by an alternative feature serving the same, equivalent, orsimilar purpose. Thus, unless expressly stated otherwise, each featuredisclosed is only an example of a generic series of equivalent orsimilar features.

From the above description, one skilled in the art can easily ascertainthe essential characteristics of the present invention, and withoutdeparting from the spirit and scope thereof, can make various changesand modifications of the invention to adapt it to various usages andconditions. Thus, other embodiments are also within the scope of thefollowing claims.

1. An aqueous solution comprising 0.1-50 mg of vitamin B1, 0.1-150 mg ofvitamin B2, 0.1-2000 mg of vitamin B3, 0.1-200 mg of vitamin B6, 5-150μg of vitamin B12, 50-2000 mg of vitamin C, 50-1500 mg of caffeine,20-2000 mg of quercetin, 10-500 mg of epigallocatechin gallate, 10-500mg of epicatechin, 10-500 mg of epicatechin gallate, 10-500 mg ofepigallocatechin, and 10-500 mg of polypheron E per liter of thesolution.
 2. The solution of claim 1, wherein the solution comprises20-50 mg of vitamin B1, 10-150 mg of vitamin B2, 10-2000 mg of vitaminB3, 10-200 mg of vitamin B6, 10-150 μg of vitamin B12, 50-1000 mg ofvitamin C, 50-1000 mg of caffeine, 50-2000 mg of quercetin, 20-500 mg ofepigallocatechin gallate, 20-400 mg of epicatechin, 20-400 mg ofepicatechin gallate, 20-400 mg of epigallocatechin, and 20-400 mg ofpolypheron E per liter of the solution.
 3. The solution of claim 2,further comprising 3-1000 IU of vitamin E per liter of the solution. 4.The solution of claim 3, wherein the solution comprises 10-1000 IU ofvitamin E per liter of the solution.
 5. The solution of claim 4, furthercomprising 1-400 mg of CoQ-10, 20-600 mg of soy isoflavones, 10-1000 mgof taurine, 1-15 g of sugar beet pectin fiber, or 50-500 mg of a ginkobiloba extract per liter of the solution.
 6. The solution of claim 5,wherein the solution comprises 20-400 mg of CoQ-10, 30-500 mg of soyisoflavones, 50-1000 mg of taurine, 5-15 g of sugar beet pectin fiber,or 50-300 mg of a ginko biloba extract per liter of the solution.
 7. Thesolution of claim 1, further comprising 3-1000 IU of vitamin E per literof the solution.
 8. The solution of claim 7, wherein the solutioncomprises 10-1000 IU of vitamin E per liter of the solution.
 9. Thesolution of claim 8, further comprising 10-400 mg of CoQ-10, 20-600 mgof soy isoflavones, 10-1000 mg of taurine, 1-15 g of sugar beet pectinfiber, or 50-500 mg of a ginko biloba extract per liter of the solution.10. The solution of claim 9, wherein the solution comprises 20-400 mg ofCoQ-10, 30-500 mg of soy isoflavones, 50-1000 mg of taurine, 5-15 g ofsugar beet pectin fiber, or 50-300 mg of a ginko biloba extract perliter of the solution.
 11. The solution of claim 1, further comprising10-400 mg of CoQ-10, 20-600 mg of soy isoflavones, 10-1000 mg oftaurine, 1-15 g of sugar beet pectin fiber, or 50-500 mg of a ginkobiloba extract per liter of the solution.
 12. The solution of claim 11,wherein the solution comprises 20-400 mg of CoQ-10, 30-500 mg of soyisoflavones, 50-1000 mg of taurine, 5-15 g of sugar beet pectin fiber,or 50-300 mg of a ginko biloba extract per liter of the solution.
 13. Acomposition comprising 0.1-50 mg of vitamin B1, 0.1-150 mg of vitaminB2, 0.1-2000 mg of vitamin B3, 0.1-200 mg of vitamin B6, 5-150 μg ofvitamin B12, 50-2000 mg of vitamin C, 50-1500 mg of caffeine, 20-2000 mgof quercetin, 10-500 mg of epigallocatechin gallate, 10-500 mg ofepicatechin, 10-500 mg of epicatechin gallate, 10-500 mg ofepigallocatechin, and 10-500 mg of polypheron E, or in quantities of thesame ratio.
 14. The composition of claim 13, wherein the compositioncomprises 20-50 mg of vitamin B1, 10-150 mg of vitamin B2, 10-2000 mg ofvitamin B3, 10-200 mg of vitamin B6, 10-150 μg of vitamin B12, 50-1000mg of vitamin C, 50-1000 mg of caffeine, 50-2000 mg of quercetin, 20-500mg of epigallocatechin gallate, 20-400 mg of epicatechin, 20-400 mg ofepicatechin gallate, 20-400 mg of epigallocatechin, and 20-400 mg ofpolypheron E, or in quantities of the same ratio.
 15. The composition ofclaim 14, further comprising 3-1000 IU of vitamin E, or in quantities ofthe same ratio.
 16. The composition of claim 15, wherein the compositioncomprises 10-1000 IU of vitamin E, or in quantities of the same ratio.17. The composition of claim 16, further comprising 10-400 mg of CoQ-10,20-600 mg of soy isoflavones, 10-1000 mg of taurine, 1-15 g of sugarbeet pectin fiber, or 50-500 mg of a ginko biloba extract, or inquantities of the same ratio.
 18. The composition of claim 17, whereinthe composition comprises 20-400 mg of CoQ-10, 30-500 mg of soyisoflavones, 50-1000 mg of taurine, 5-15 g of sugar beet pectin fiber,or 50-300 mg of a ginko biloba extract, or in quantities of the sameratio.
 19. The composition of claim 13, further comprising 3-1000 IU ofvitamin E, or in quantities of the same ratio.
 20. The composition ofclaim 19, wherein the composition comprises 10-1000 IU of vitamin E, orin quantities of the same ratio.
 21. The composition of claim 20,further comprising 10-400 mg of CoQ-10, 20-600 mg of soy isoflavones,10-1000 mg of taurine, 1-15 g of sugar beet pectin fiber, or 50-500 mgof a ginko biloba extract, or in quantities of the same ratio.
 22. Thecomposition of claim 21, wherein the composition comprises 20-400 mg ofCoQ-10, 30-500 mg of soy isoflavones, 50-1000 mg of taurine, 5-15 g ofsugar beet pectin fiber, or 50-300 mg of a ginko biloba extract, or inquantities of the same ratio.
 23. The composition of claim 13, furthercomprising 10-400 mg of CoQ-10, 20-600 mg of soy isoflavones, 10-1000 mgof taurine, 1-15 g of sugar beet pectin fiber, or 50-500 mg of a ginkobiloba extract, or in quantities of the same ratio.
 24. The compositionof claim 23, wherein the composition comprises 20-400 mg of CoQ-10,30-500 mg of soy isoflavones, 50-1000 mg of taurine, 5-15 g of sugarbeet pectin fiber, or 50-300 mg of a ginko biloba extract, or inquantities of the same ratio.